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Oestradiol and tamoxifen inhibit murine Colon 38 cancer
growth and increase the cytotoxic effect of fluorouracil
Estradiol i tamoksyfen hamują wzrost mysiego raka jelita grubego
Colon 38 oraz nasilają cytotoksyczne działanie fluorouracylu
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Department of Immunoendocrinology, Chair of Endocrinology, Medical University, Łódź
Abstract
The poor efficacy of reference chemotherapy (fluorouracil -FU) in colon cancer has resulted in a constant search for agents
which could augment the action of FU. Epidemiological data, such as the decreased risk of colorectal cancer among meno-
pausal women receiving hormonal replacement therapy, indicate the role of oestrogen in the pathogenesis of this disease.
The differences between normal and neoplastic colon cells in the expression of oestrogen receptor b (ERb) could confirm
this association. However, the direct influence of oestrogen or tamoxifen (SERM, selective oestrogen receptor modulator)
on colon cancer growth has rarely been studied.
The aim of the present study was to examine the direct effects of various concentrations of oestradiol and tamoxifen (10–4 to
10–12 M), applied alone or together with FU, on the growth of murine Colon 38 cancer in vitro as assessed by three colorime-
tric methods: Mosmann’s method, incorporation of BrdU into cell nuclei and the TUNEL method.
At high concentrations oestradiol and tamoxifen decreased the cancer growth in a dose- and time-dependent manner (the
Mosmann and BrdU methods) and at some concentrations augmented the cytotoxic action of FU (Mosmann’s method).
Tamoxifen exerted a very early and potent inhibitory effect, inducing even total cancer growth inhibition at the concentra-
tion of 10–4 M (the Mosmann and BrdU methods). All the substances studied at different concentrations and at different
incubation time points increased the apoptosis of tumour cells (the TUNEL method).
The results indicate that oestradiol and tamoxifen inhibit Colon 38 cancer growth and increase the cytotoxic effect of FU,
which confirms the role of sex steroids in colon carcinogenesis and even suggests new therapeutic schemes.
(Pol J Endocrinol 2007; 58 (5): 426–434)
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Streszczenie
Niezadowalająca skuteczność fluorouracylu (FU) w leczeniu uzupełniającym raka jelita grubego skłania do poszukiwania
nowych leków, w tym substancji nasilających przeciwnowotworowe działanie tego cytostatyku. Protekcyjną rolę estroge-
nów w karcynogenezie jelita grubego sugerują wyniki badań epidemiologicznych wykazujące zmniejszenie ryzyka roz-
woju tego nowotworu u kobiet przyjmujących hormonalną terapię zastępczą (HTZ), a także różnice w ekspresji receptora
estrogenowego b (ERb) w prawidłowych i nowotworowych kolonocytach. Jednak badania doświadczalne nad bezpośred-
nim wpływem estrogenów lub tamoksyfenu (selektywnego modulatora receptorów estrogenowych) na wzrost raka jelita
grubego są nieliczne, a ich wyniki niejednoznaczne.
Celem pracy było zbadanie bezpośredniego wpływu estradiolu i tamoksyfenu w stężeniach od 10–4 do 10–12 M stosowanych
osobno lub łącznie z FU na wzrost mysiej linii raka jelita grubego Colon 38 oceniany za pomocą 3 metod kolorymetrycz-
nych: metody Mosmanna, metody opartej o wbudowywanie BrdU i metody TUNEL.
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Estradiol i tamoksyfen hamowały wzrost badanej linii w wąskim zakresie wysokich stężeń z siłą narastającą wraz ze stęże-
niem leku i czasem trwania inkubacji (metoda Mosmanna i BrdU), a w wybranych stężeniach potęgowały cytotoksyczne
działanie FU (metoda Mosmanna). Tamoksyfen wywoływał bardzo wczesny i silny efekt hamujący, powodując nawet
całkowite zahamowanie wzrostu tej linii w stężeniu 10–4 M (metoda Mosmanna i BrdU). Wszystkie badane substancje
w wybranych stężeniach i w określonych punktach czasowych nasilały apoptozę komórek tego raka (metoda TUNEL).
Uzyskane wyniki wskazują, że estradiol i tamoksyfen hamują wzrost raka Colon 38, a także nasilają cytotoksyczne działa-
nie FU, co potwierdza udział hormonów płciowych w karcynogenezie jelita grubego, a potencjalne sugeruje nawet nowe
schematy lecznicze.
(Endokrynol Pol 2007; 58 (5): 426–434)
Słowa kluczowe: estradiol, tamoksyfen, fluorouracyl, proliferacja, apoptoza, rak jelita grubego
the 37% reduction in colon cancer risk in users of com-
bined oestrogen and progestin HRT [8]. However, in
the parallel trial of oestrogen alone in women after hy-
sterectomy the protective effect was not observed [9].
Interestingly, the colon cancers which occurred among
women using HRT were characterised by a greater num-
ber of positive lymph nodes and were more advanced [10].
Differences in the expression of oestrogen receptors
(ER) in normal colonocytes and colon cancer cells also
suggest the role of oestrogen in colorectal carcinogene-
sis. ERa is reported to be minimally expressed in nor-
mal colon mucosa and colon cancer cells [11, 12], whe-
reas the predominant ER subtype in the human colon
is ERb and its expression declines in colon cancer [11–13].
Therefore some authors even suggest a potential use
for ERb agonists in colon cancer treatment [14].
Furthermore, the role of local oestrogen metabolism
seems to be pivotal in the pathogenesis of colon cancer.
A change in 17b-hydroxysteroid dehydrogenase (17b-HSD)
activity, which is responsible for the interconversion
of oestradiol (E2) to oestrone (E1), has been revealed
in colon tumours. A decreased oxidative activity of
17b-HSD in colon cancer lines in vitro [15] and a reduc-
tion in the expression of 17a-HSD isoform 2 in colon
cancer tissues in vivo [16] correlated inversely with cell
proliferation.
The number of studies examining the direct effect
of oestrogen on colon cancer growth is limited and the-
se have often given conflicting results. Studies in vitro
and experiments with ovariectomised animals have
shown that oestrogen can inhibit as well as stimulate
colon cancer growth [17–20].
The positive effects of hormonal modulation in the
treatment of prostate and breast cancers are well known.
One of the most commonly used drugs in breast cancer
adjuvant therapy is tamoxifen. This is one of the group
of selective oestrogen receptor modulators (SERMs) and
after binding to oestrogen receptors (ER) it exerts oestro-
genic effects on certain genes while having anti-oestro-
genic effects on others. This mixed action of tamoxifen
is species-, tissue- and cell-dependent [21]. There are
Introduction
In the developed countries colorectal cancer represents
a major health problem [1]. In Poland too colorectal can-
cer is one of the most common cancers and its inciden-
ce and mortality rates are still growing. Approximately
30% of all patients with colon cancer have metastatic
disease at diagnosis, and the other 50% of patients will
eventually develop it [2]. For many years fluorouracil
(FU) has remained the main chemotherapeutic agent
in this cancer. Modulation of its anti-neoplastic effects
by leucovorin became one of the standard treatment
regimens for advanced stages of colon cancer. Combi-
ning it with other known agents has not improved pa-
tient survival [2]. However, during the last decade the
USA Food and Drug Administration (FDA) has appro-
ved five new drugs for the treatment of advanced co-
lon cancer. Among these are three cytotoxic agents: iri-
notecan (1996), oxaliplatin (2002), the oral formulation
of fluorouracil — capecitabine (1998) and two monoc-
lonal antibodies — bevacizumab and cetuximab (2004).
The new agents doubled survival among patients but
also led to a great increase in drug costs. The average
survival is still little more than 20 months, and the tre-
atment remains palliative [3].
The positive results of colon cancer treatment with
bevacizumab (targeting vascular endothelial growth
factor) and cetuximab (directed against epithelial
growth factor receptor) confirm the effectiveness of bio-
therapy in cancer treatment [2, 4, 5].
The potential role of oestrogens in the pathogenesis
of colon cancer has been discussed for many years. This
association is suggested by epidemiological data such
as sex differences in site-specific incidences of colorec-
tal cancer, its increased occurrence in women with bre-
ast cancer and the protective effect of increasing parity
[6]. The protective effects of hormonal replacement the-
rapy (HRT) on colon cancer are supported by a number
of observational studies [7]. A randomised primary pre-
vention trial, the Women’s Health Initiative (WHI), com-
prising 16 608 women aged 50–79 years, also confirmed
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also data showing other ER-independent anti-tumour
effects of tamoxifen, such as inhibition of calmodulin,
induction of TGF-a secretion, antioxidant activity and
interaction with the multi-drug resistance protein P-gly-
coprotein [22].
Thus the aim of this study was to examine the direct
effects of oestradiol and tamoxifen, applied alone or
together with FU, on murine Colon 38 cancer growth
in vitro as assessed by methods reflecting changes in
proliferation and apoptosis.
Materials and methods
Murine Colon 38 cancer cells were used in the study.
The cells were routinely grown in a humidified incuba-
tor at 370 C with 5% CO2 in RPMI 1640 medium (Sig-
ma), supplemented with the following: 25 nM Hepes
buffer (Sigma), 4 mM L-glutamine (Sigma), 100 U/ml
penicillin and 100 mg/ml streptomycin solution (Sigma),
2 g/l sodium bicarbonate (Sigma) and 5% foetal calf se-
rum (FCS, Biochrom). The cells were passaged every
7 days with 0.05% trypsin/0.02% EDTA (Trypsin-EDTA,
Sigma) and the medium was changed every 3–4 days.
After one of the trypsinisation procedures the cells
were plated (depending on time and method: 20 000–
–30 000/well for the Mosmann and BrdU methods and
60 000–90 000/well for the TUNEL method) into
96-multiwell plates (Nunc). To avoid the influence of
oestrogens and oestrogen-like substances the cells were
cultured in phenol red-free RPMI 1640 medium (Sig-
ma) supplemented with 5% charcoal-treated hormone-
free FCS (Biochrom). After preincubation (24 h) the cells
were cultured for a further 1, 4, 8, 12, 24 or 72 h in the
presence of various concentrations of the substances
examined (fluorouracil, oestradiol and tamoxifen), ap-
plied alone or in combination.
To assess the interaction with other substances, FU
(Fluoro-uracil, Roche) was used at concentration of
1 mM. This was chosen from a wide range of examined
concentrations (1–1024 mM; data not shown) as inducing
minor cancer growth inhibition. The control group for
FU received the medium. Oestradiol (17-b-oestradiol
17-hemisucinate, ICN Biomedicals Inc.) and tamoxifen
(Tamoxifen, Sigma) were dissolved in absolute ethanol
(in a proportion of 1 mg/1ml and 1mg/650 ml, respecti-
vely) and were examined in the range of concentrations
from 10–4 to 10–12 M. Control cells received an adequate
concentration of the ethanol vehicle without the test
substance (maximum ethanol concentration: 3.7 vol%).
Cancer growth was assessed by the three colorime-
tric methods:
— the Mosmann method (Easy for You, The 4th Gene-
ration Non-Radioactive Cell Proliferation & Cytoto-
xity Assay, Biomedica Gruppe, Austria, Bellco
Biomedica. Poland) based on the measurement of the
total metabolic activity of the cultured cells, which
reflects changes in proliferation and cell death;
— a method based on bromodeoxiuridin incorporation
into the cell nuclei (Cell Proliferation ELISA, BrdU;
Roche Applied Science), directly correlating with cell
proliferation;
— the terminal deoxynucleotidyl transferase-mediated
dUTP nick end labelling (TUNEL) method (Titer
Tacs, R&D) of evaluating cell apoptosis.
In the BrdU incorporation method BrdU was added
to each well 4 h prior to termination of the experiment.
The intensity of the reaction was estimated by me-
ans of measurement of the optical density (OD) using
an ELISA reader (l = 450 nm). The statistical significan-
ce was determined using one-way ANOVA with a post-
hoc least significant difference (LSD) or non-parame-
tric Mann Whitney test. P < 0.05 was considered to be
a statistically significant difference. The correlation be-
tween cancer growth inhibition and concentrations of
the examined substances or the duration of cultures was
determined by Pearson’s r coefficient, and the significan-
ce of differences was then analysed with Student’s t-test.
The results obtained in the BrdU incorporation and
Mosmann methods were presented as a percentage of
the OD of the control group. The results of the cell apop-
tosis measurement were shown as an apoptotic index,
calculated as previously described by other authors [23]
as a ratio of the total amount of apoptosis, as measured
by the TUNEL method, per cell number equivalent, as
measured by the Mosmann method, in adequate sam-
ples.
Results
Oestradiol in the narrow range of high concentrations
(10–5 to 10–4 M) inhibited Colon 38 cancer growth in
a time- and dose-dependent manner (Fig. 1 and 2;
Tab. I). The onset of its effect was observed in the 12 h
culture in both methods (Mosmann and BrdU). Howe-
ver, after 12 h incubation the cancer growth inhibition
of both examined oestradiol concentrations (4 × 10–5 and
10–4M) was revealed only by the Mosmann method,
while the BrdU incorporation method detected the in-
hibitory effect exclusively of the higher concentration
of E2 (Fig. 2). Oestradiol at some concentrations (10–7 to
10–4M) enhanced the cytotoxic action of FU used at the
concentration of 1 mM (Fig. 3). Interestingly, this additi-
ve effect was also observed for oestradiol at concentra-
tions of 10–7, 10–6, and 4 × 10–6 M, at which this hormone
applied alone was ineffective. Oestradiol in 24 h cultu-
re induced cancer cell apoptosis at concentrations of
4 × 10–5 and 10–4 M and after 72 h incubation at concen-
trations of 10–4 M (Fig. 4).
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Moreover, tamoxifen at concentrations of 8 x 10–5 and
10–4 M even evoked complete cell growth inhibition (Fig. 5).
Like oestradiol, tamoxifen (8 × 10–6 and 10–5 M) intensi-
fied the cytotoxic action of FU (Fig. 7). The proapopto-
tic effect of tamoxifen (10–5 and 4 × 10–5 M) was stron-
ger and observed earlier than the effect of oestradiol. Ta-
moxifen induced apoptosis after 8, 24 and 72 h (Fig. 4).
Discussion
In the present study we have shown that oestradiol and
tamoxifen inhibited Colon 38 cancer growth by influ-
encing proliferation and apoptosis and increased the
cytotoxic action of FU. Our results are consistent with
recent reports demonstrating that oestradiol evoked
growth inhibition of human colon cancer cell lines [24,
26] and that its proapoptotic activity could be involved
in this action [17]. However, some authors did not ob-
serve any such effect [27, 28] or even reported the op-
posite, that oestrogen had a stimulatory effect on cultu-
red colon cancer cells [18, 25, 26]. These conflicting fin-
dings from different studies may be due to different
types of cell lines, different oestrogen receptor patterns
and variations in the concentration of oestradiol. It was
revealed that most of the colon cancer lines (HCT8,
HCT116, DLD-1, LoVo, HT29, Colo320, SW480, CACO-2,
SW620, COLO205) expressed ERb [17, 26–28], whereas
ERa was rarely detected [17]. As noticed by some au-
thors [27] the stimulatory effect of oestradiol was de-
monstrated only in two colon cancer lines (the hu-
man Caco-2 and mouse MC-26 lines) and both were
characterised by expression of ERa [18, 25]. Moreover,
oestrogens induced colon cancer cell apoptosis only in
one (COLO205) of the four lines examined. All four
lines expressed ERb, while only COLO205 did not
Figure 1. The effect of oestradiol (E2) on the growth of Colon 38 cancer as assessed by the Mosmann method in 72 h culture. X ± SEM,
*p < 0.05 vs. control
Rycina 1. Wpływ estradiolu (E2) na wzrost raka Colon 38 oceniany metodą Mosmanna w hodowli 72 h. X ± SEM, *p < 0,05 vs. kontrola
Figure 2. The effect of oestradiol (E2) on the growth of Colon 38
cancer as assessed by the Mosmann method and BrdU
incorporation method in 4, 12, 24 and 72 h cultures
Rycina 2. Wpływ estradiolu (E2) na wzrost raka Colon 38 oceniany
metodą Mosmanna i metodą wbudowywania BrdU w hodowlach
4, 12, 24 i 72 h
Tamoxifen in the narrow range of high concentra-
tions (10–5 to 10–4 M) exerted a strong inhibitory effect
on cancer growth (Fig. 5), which was revealed (for con-
centrations 10–4 and 4 × 10–5 M) as early as after 4 h of
incubation (Mosmann and BrdU method) (Fig. 6). Using
tamoxifen in this range of concentration we also obse-
rved a time- and dose-response effect (Fig. 6; Tab. I).
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Table I
The correlations between Colon 38 cancer growth inhibition as assessed by the Mosmann or BrdU incorporation methods and
concentrations of the substances examined (E2 — oestradiol, T — tamoxifen) or duration of cultures, r — Pearson coefficient,
“–“ not determined, NS — not significant
Tabela I
Korelacja pomiędzy zahamowaniem wzrostu raka Colon 38 ocenianym metodą Mosmanna lub wbudowywaniem BrdU
a stężeniem badanych substancji (E2 — estradiol, T — tamoksyfen) lub czasem trwania hodowli, r — współczynnik korelacji
Pearsona, „–„ nie oceniano, NS — statystycznie nieznamienne
Mosmann method BrdU method
 r p  r p
E2 dose (10–5 to 10–4 M) — response –0.9149 0.0000 – –
time (4–72 h) – response 4 × 10–5 M –0.6915 0.0002 –0.6338 0.0010
10–4 M –0.8274 0.0000 –0.9358 0.0000
T dose (10–5 to 10–4 M) — response –0.9386 0.0000 – –
time (4–72 h) — response 10–5 M –0.7433 0.0002 –0.7129 0.0003
4 × 10–5 M –0.5332 0.0069 –0.5612 0.0050
10–4 M –0.1283 NS –0.5432 0.0084
Figure 3. The effect of oestradiol (E2) applied alone or jointly with fluorouracil (FU) on the growth of Colon 38 cancer as assessed by the
Mosmann method in 72 h culture. X±SEM, *p < 0.05 vs. control , ^p < 0.05 vs. FU1, #p < 0.05 vs. E2 10–4. FU1 — fluorouracil
1 mM; E2 10–7, E2 10–4 — oestradiol 10–7 M, oestradiol 10–4 M
Rycina 3. Wpływ estradiolu (E2) zastosowanego oddzielnie lub w połączeniu z fluorouracylem (FU) na wzrost raka Colon 38 oceniany
metodą Mosmanna w hodowli 72 h. X±SEM, *p < 0,05 vs. kontrola, ^p < 0,05 vs. FU1, #p < 0,05 vs. E2 10–4. FU1 — fluorouracil
1 mM; E2 10–7, E2 10–4 — estradiol 10–7 M, estradiol 10–4 M
express ERa [17]. It is therefore suggested that ERa and
ERb may function in opposite ways in these cells. Inte-
restingly, in this study LoVo colon cancer cells were
shown to express ERa, which was not detected in these
cells by other authors [27], although they used the same
method (RT-PCR). However, from both subtypes of ER,
the pivotal role in colon cancer growth regulation se-
ems to be played not by ERa, but by ERb. Over-expres-
sion of ERb in an engineered human colon cancer line
inhibited cell proliferation and increased adhesion in a
ligand-independent manner [29]. In our study we re-
vealed that Colon 38 cancer cells express ERb (data not
published). We therefore suppose that the inhibitory
effect of oestradiol found in our experiments can be
mediated by this receptor.
The diverse effect of oestrogens on colon cancer
growth observed in various studies might also be lin-
ked to the use of different concentrations of oestradiol.
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It has been suggested that oestradiol at low concentra-
tions enhances cell proliferation, while reducing it at
high concentrations [26]. Thus we examined the influ-
ence of oestradiol in a wide range of concentrations
(from 10–12 to10–4M). In our study we observed exclusi-
vely the inhibitory effect of oestradiol, which was evo-
ked by the hormone at high concentrations (between
10–5 and 10–4 M). However, in one of the shorter (24 h)
cultures oestradiol at low concentrations (10–6 to 10–12
M) seemed to stimulate cancer growth. This effect tur-
ned out to be an error connected with a badly matched
control group. Unexpectedly, the highest ethanol con-
centration routinely used in 72 h experiments as the only
control group for all oestradiol concentrations (10–4 to
10–12 M) was shown to inhibit control cell growth in cul-
tures lasting 24 h or less. This unwanted control cell
growth inhibition resulted in the apparent stimulatory
effect of lower oestradiol concentrations containing
a smaller amount of ethanol solvent. This experience
persuaded us to use, in shorter experiments, multiple
control groups with the full range of ethanol concen-
trations adequate for the ethanol concentrations pre-
sent in the groups examined.
In this study tamoxifen at high concentrations (betwe-
en 10–5 and 10–4 M) decreased Colon 38 cell proliferation
with great potency, even causing total cancer growth
inhibition at concentrations of 8 x 10–5 and 10–4M. These
results are compatible with other studies, in which ta-
moxifen at various concentrations inhibited colon can-
cer growth [24, 27, 28, 30, 31]. Moreover, some authors
have demonstrated that tamoxifen at a concentration of
10–5 M were lethal to colon cancer cells [28, 30]. It is
known that tamoxifen can exert anti-oestrogenic and
oestrogenic effects, which are tissue- , cell- and gene-
dependent [21]. In our study tamoxifen and oestradiol
alike inhibited colon cancer growth. In agreement with
our study, other authors have observed the same inhi-
bitory effect of these two compounds at a similar range
of concentrations [24].
To our knowledge, we have revealed for the first
time that oestradiol and tamoxifen can enhance the cy-
totoxic effect of FU on colon cancer cells. However, it
has been shown in vitro that oestradiol, which did not
inhibit colon cancer growth when given alone, intensi-
fied the inhibiting effect of tamoxifen [28]. Furthermo-
re, the compounds applied together increased cellular
sensitivity to FU [28]. The interaction of tamoxifen and
FU was examined using two gastric cancer lines. The
combination therapy of these two drugs resulted in
a synergistic anti-proliferative activity on one line and
an antagonistic effect on another line, in which tamoxi-
fen attenuated the cytotoxic effect of FU [32]. Moreover,
it was reported that tamoxifen can reverse drug (doxo-
Figure 4. Effect of oestradiol (E2) and tamoxifen (T) on apoptosis
of Colon 38 cancer cells in 8, 24 and 72 h cultures. Me (Max-
-Min), ^p < 0.05 vs. control (C)
Rycina 4. Wpływ estradiolu (E2) i tamoksyfenu (T) na nasilenie
apoptozy komórek raka Colon 38 w hodowlach 8, 24 i 72 h. Me
(Max-Min), *p < 0,05 vs. kontrola medium, ^p < 0,05 vs.
kontrola (C)
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rubicin) resistance in different tumours including co-
lon cancer [33, 34].
It was demonstrated in vitro [35, 37] and in vivo [36]
that tamoxifen can activate the apoptosis pathway in
various cancers. An in vitro study on HeLa cells sho-
wed that tamoxifen at concentrations of 10–20 mM in-
duced apoptosis in an ER-independent way, while at
submicromolar concentrations it did so in an ER-depen-
dent way [37]. In our apoptosis assay we examined the
effect of tamoxifen only at high concentrations (from
10–5 to 10–4 M), demonstrating its proapoptotic effect at
a concentration of 10–5 and 4 × 10–5 M. This is in agre-
ement with our earlier studies, where tamoxifen only
at higher doses induced apoptosis in transplantable
Colon 38 cancer [36], while lower doses were ineffecti-
ve [38]. On the other hand, tamoxifen at the concentra-
tions similar to the concentrations used by us did not
induce apoptosis in two other colon cancer lines (HCT8,
HCT116) [30].
Conclusions
To summarise, we have shown in this article that oestra-
diol and tamoxifen inhibit Colon 38 cancer growth thro-
ugh their anti-proliferative and proapoptotic effects.
Moreover, both substances enhanced the cytotoxic ef-
fect of FU. Our results suggest that sex steroids are in-
volved in colon carcinogenesis. We also hypothesise that
oestrogens and an oestrogen receptor modulator (ta-
moxifen) may potentially be useful in colon cancer tre-
atment by enhancing the efficacy of FU. Further stu-
dies are needed to elucidate whether this suggestion is
true in human colon cancer and whether it merits clini-
cal application.
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